Adimab spinout aims for neutralizing mAbs more effective than coronavirus vaccines

Adagio spun out of Adimab Thursday with neutralizing antibodies against a conserved epitope of the SARS-CoV-2 spike protein that it believes are potent enough to yield a bi-annual prophylaxis with better efficacy than vaccines. The start-up, co-founded by Adimab co-founder and CEO Tillman Gerngross, also thinks the therapies could protect against future coronaviruses.

Adagio Therapeutics Inc. has raised $50 million in a series A round led by Polaris Partners and Mithril Capital with a near-term goal of advancing the first neutralizing mAb program into the clinic by year-end. Longer term, the newco aims to produce up to 60 million doses per year from one 100,000-liter reactor. Fidelity Management & Research Co., OrbiMed, M28 Capital and GV also participated in the venture round. ...